Designing Longevity
Skip to main content
Strong EvidenceSmall molecule

Orforglipron

The GLP-1 pill

Oral Non-Peptide GLP-1 Receptor Agonist

Last updated: October 2026
Share:

Evidence Level: Strong Evidence

Multiple large human trials, FDA approval, established safety profile

Regulatory Status: FDA-approved April 1, 2026 as Foundayo, for long-term weight reduction in adults with obesity, or overweight with at least one weight-related condition, alongside reduced-calorie diet and increased physical activity. Approval applies to the labeled tablets, not other orforglipron products.

Orforglipron is a small-molecule, once-daily pill. The FDA approved the finished tablet Foundayo in April 2026 for long-term weight reduction in certain adults. In the FDA label's Trial 1, the 17.2 mg group lost an average of 11.1% of body weight over 72 weeks. It may be taken with or without food.

How It Works

Orforglipron does the same job as : it activates the receptor, which slows stomach emptying, blunts appetite, and improves how your body handles blood sugar. If you want the full mechanism, our semaglutide guide covers it in detail.

What is genuinely different is the chemistry, and it matters more than it sounds.

It is not a peptide. We list it on this page because that is where people look for it, but orforglipron is a small molecule, not a peptide. and are chains of amino acids; injected formulations avoid digestion, while oral semaglutide (Rybelsus) uses an absorption enhancer and must be taken on an empty stomach with strict timing rules.

That chemistry is why the rules are so relaxed. Because orforglipron is a small molecule that survives digestion on its own, it does not need food or water restrictions and does not need to be taken at a particular time of day. For a drug people take for years, "just swallow it whenever" is a bigger deal than it sounds.

It also changes the supply picture. Peptide drugs require complex biological manufacturing, which is a large part of why shortages happened. Small molecules are made by conventional chemical synthesis, which scales far more easily and cheaply. That is the reason a lot of analysts expect oral GLP-1s to be what finally makes this drug class affordable.

Evidence by Outcome

Each claim below is rated using a GRADE-aligned five-tier system. Same molecule, different outcomes, different evidence.

Evidence at a glance

How we grade

Want to see how this compares to every other peptide? Browse the full evidence matrix, where every graded claim is grouped by outcome and sorted by certainty.

Weight lossHigh certainty

The FDA label's Trial 1 reports 11.1% average body-weight loss over 72 weeks at 17.2 mg daily in adults with obesity or qualifying overweight, without type 2 diabetes.

Population: Adults with BMI ≥30, or ≥27 with at least one weight-related condition, without type 2 diabetes

Why this rating

Direct evidence from a large trial summarized in the current FDA label, with a dose response and patient-relevant outcomes. This grade concerns the labeled product and population; the earlier published 36 mg study notation and 12.4% result should not be substituted for the approved tablet strength and FDA label estimate.

Supporting studies

Reviewed October 2026· Designing Longevity EditorialHow we grade
Cardiovascular outcomesModerate certainty

Improves waist circumference, systolic blood pressure, lipids, and glycemic markers.

Population: Adults with obesity or overweight with a weight-related condition

Why this rating

These were pre-specified secondary endpoints in a large RCT and all moved in the expected direction. They are downgraded from high because they are risk markers rather than hard outcomes like heart attack or stroke, which orforglipron has not yet been shown to reduce.

GRADE downgrade factors applied

  • Indirectness: Studied population, intervention, comparator, or outcome differs from the question being answered.

Supporting studies

Reviewed October 2026· Designing Longevity EditorialHow we grade

Potential Benefits

  • A pill, not an injection, with no needles, no , and no sharps disposal
  • No food or water restrictions and no required time of day, unlike oral
  • In the FDA label's Trial 1, average 11.1% body-weight loss at 72 weeks on 17.2 mg daily
  • 54.5% of patients in the FDA label's Trial 1 on 17.2 mg lost at least 10% of body weight
  • Improved waist circumference, blood pressure, lipids, and blood sugar
  • Small-molecule manufacturing scales more easily than peptide manufacturing, which should ease supply and pricing pressure

Risks & Considerations

  • Weight-loss figures from separate trials of different drugs are not direct head-to-head comparisons
  • Same gastrointestinal side effects as the rest of the class: nausea, vomiting, diarrhea, constipation
  • 5% to 10% of participants stopped the drug because of side effects, versus 3% on placebo
  • Daily dosing means daily adherence, which is harder for some people than a weekly shot
  • Weight tends to return after stopping, as with every drug in this class
  • Long-term safety data is thinner than for , which has been in use since 2017

Dosing Information

The approved Foundayo tablet is taken once daily with or without food. Its FDA label gives a maximum of 17.2 mg daily, with stepwise increases. The earlier ATTAIN-1 publication used different dose notation; its 36 mg figure should not be read as a marketed tablet strength.

  • •The FDA-approved tablets range from 0.8 mg to 17.2 mg; the label's Trial 1 reports the marketed 17.2 mg group
  • •Doses are titrated up over several months rather than started at target
  • •No food, water, or timing restrictions, which is the main practical advantage over Rybelsus
  • •Missing doses matters more than with weekly injectables, since the drug clears faster
  • •Available through LillyDirect and, since 2026, standard pharmacy and telehealth channels

Need to mix this from a vial?

Use our reconstitution calculator to get the exact insulin syringe units to draw.

Practical Tips

  • 1If needle avoidance is the reason you have not started a , this is the drug that solves that problem
  • 2If maximum weight loss is the priority and you can tolerate an injection, still wins on the numbers
  • 3Escalate slowly. Most of the nausea in trials happened during dose increases, not at steady state
  • 4Set a daily reminder. Daily pills are easier to forget than a weekly ritual
  • 5Compare cash pricing against options before assuming the pill is cheaper

Key Research

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1)

New England Journal of Medicine, 2025

Historical published ATTAIN-1 study notation: the 36 mg group lost an average of 12.4% of body weight at 72 weeks. This is not the labeled Foundayo tablet strength or the FDA label efficacy estimate; see the current FDA label below.

View Study

Current FDA prescribing information for Foundayo (orforglipron)

US Food and Drug Administration, 2026

Approved Foundayo tablets are for long-term weight reduction in the labeled adult population. Trial 1 reports 11.1% mean weight loss at 72 weeks for 17.2 mg daily.

View Study

Want to learn more?

Explore related content and talk to a healthcare provider.

Browse All TreatmentsFind Your Goal

Always consult a healthcare provider before starting any treatment.

Frequently Asked Questions

What is orforglipron?

Orforglipron is a once-daily small-molecule pill that activates the receptor. The FDA approved the finished tablet Foundayo on April 1, 2026 for long-term weight reduction in adults with obesity or overweight with a weight-related condition. It may be taken with or without food. Oral was available earlier; Foundayo is a different drug.

Is orforglipron a peptide?

No. This is a common point of confusion. and are peptides, meaning chains of amino acids, which is why they have to be injected. Orforglipron is a small molecule that happens to activate the same receptor. That difference is exactly why it survives digestion and can be taken as an ordinary pill. We list it alongside peptides because that is where people go looking for it.

How much weight can you lose on orforglipron?

The current FDA label reports average body-weight loss of 11.1% over 72 weeks in Trial 1 for the 17.2 mg daily group; 54.5% lost at least 10%. An earlier ATTAIN-1 publication used 36 mg notation and reported 12.4%; it is a historical study figure, not the marketed tablet strength or FDA label estimate.

Is orforglipron as good as Ozempic or Zepbound?

The FDA label reports 11.1% mean weight loss at 72 weeks for its 17.2 mg group without diabetes. and results come from separate trials in different populations, so those percentages do not establish which drug works better for an individual. Foundayo offers once-daily oral dosing with or without food.

How is orforglipron different from Rybelsus?

Rybelsus is oral , a peptide packaged with an absorption enhancer to survive the stomach. It has to be taken on an empty stomach with no more than 4 ounces of water, and you have to wait 30 minutes before eating or drinking anything else. Orforglipron is a small molecule that absorbs on its own, so it has no food, water, or timing restrictions at all.

What are the side effects of orforglipron?

The same profile as other drugs, with gastrointestinal effects most common: nausea, vomiting, diarrhea, and constipation, typically mild to moderate and worst during dose escalation. In ATTAIN-1, between 5% and 10% of people on orforglipron stopped because of side effects, compared with 3% on placebo.

Will orforglipron be cheaper than injectable GLP-1s?

That is the expectation, and the reason is manufacturing. Peptides require complex biological production, which is a large part of why are expensive and why shortages happened. Small molecules like orforglipron are made by conventional chemical synthesis that scales far more cheaply. At launch, Lilly quoted self-pay pricing starting around $149 per month, with some insured patients paying substantially less.

Do you regain weight after stopping orforglipron?

Yes, most people do, and this is true of every drug in this class. medications work while you take them by changing appetite signaling; they do not permanently reset your metabolism. Trials of and have consistently shown substantial regain after discontinuation, and there is no reason to expect orforglipron to behave differently.

New to Peptides?

Learn the basics of peptide therapy, how to inject safely, and what to look for in quality sources.

What Are Peptides? Peptide Safety Guide

Related Goals

The Weight Loss Guide

Related Peptides

SemaglutideGLP-1 Receptor Agonist
TirzepatideDual GLP-1/GIP Receptor Agonist
RetatrutideTriple Hormone Receptor Agonist (GLP-1 / GIP / Glucagon)

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated October 2026.

Found this helpful? Share it or save it for later.

Share: